FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912130511> ?p ?o ?g. }

• W2912130511 endingPage "S95" @default.
• W2912130511 startingPage "S94" @default.
• W2912130511 abstract "BackgroundCMV seropositive CBT recipients have a high risk of CMV infection. Early pre-emptive therapy is required to avoid CMV disease but is associated with significant toxicities.MethodsThis analysis compares the day +100 incidence & severity of clinically significant CMV infection (viremia leading to pre-emptive treatment or disease) in CMV seropositive CBT adult patients (pts) who received letermovir prophylaxis transplanted 12/2017-6/2018 vs historic controls transplanted 3/2013-12/2017. Control pts received ganciclovir prophylaxis days -7 to -2 then standard dose acyclovir. Letermovir pts received standard dose acyclovir & started letermovir IV or PO on day +7 & continued beyond day +100. All pts received uniform intermediate intensity Cy 50 mg/kg / Flu 150 mg/m2/ Thio 5-10 mg/kg / TBI 400 cGy conditioning with CSA/ MMF. Pts were monitored by qPCR twice weekly from approximately day +14-60 & then 1-2 x/weekly days +60-100.Results62 [median age 51 years (range 23-66), 46 leukemia, 7 MDS/ MPD, 9 NHL/ HL] historic control pts received double unit grafts with a median unit-recipient HLA-allele match of 5/8 (range 2-7). By day +100, 51 pts developed clinically significant CMV infection for a day +100 cumulative incidence of 82% (95%CI: 70-90). The median viremia onset was 34 days (range 5-74) & 5 pts developed CMV disease by day +100 (3 pulmonary, 2 GI). Initial therapy was with foscarnet in 28 pts & ganciclovir/ valganciclovir in 23. Clinically significant therapy toxicities (renal &/or myelosuppression) were observed in 38/51 (75%) pts (Table 1). By day +100, CMV caused or contributed to 3 pulmonary deaths. 10 pts [median age 48 years (range 24-59), 9 leukemia, 1 MDS/ MPD, median 5/8 (range 3-6) unit-recipient HLA-match] received letermovir prophylaxis (8 IV, 2 PO) (Table 2). All pts engrafted. The day +100 cumulative incidence of clinically significant CMV infection was 0% (p < 0.001 vs controls) (Figure). After letermovir was started, 3 pts had a brief low level CMV viremia that spontaneously resolved without CMV-specific therapy. Prophylaxis was well tolerated & there were no drug toxicities attributed to letermovir. By day +100, one letermovir pt died due to HHV-6 infection.ConclusionsThis analysis suggests letermovir prophylaxis is highly effective at mitigating CMV disease, CMV-related mortality, & the need for toxic CMV therapies. Moreover, it has been well tolerated in CBT recipients. While further detailed investigation in a larger population is required, this data is very promising & the extent of the benefit suggests that letermovir could be a cost-effective new standard of care in adult CBT. The duration of needed prophylaxis beyond day +100 in CBT recipients also requires investigation. CMV seropositive CBT recipients have a high risk of CMV infection. Early pre-emptive therapy is required to avoid CMV disease but is associated with significant toxicities. This analysis compares the day +100 incidence & severity of clinically significant CMV infection (viremia leading to pre-emptive treatment or disease) in CMV seropositive CBT adult patients (pts) who received letermovir prophylaxis transplanted 12/2017-6/2018 vs historic controls transplanted 3/2013-12/2017. Control pts received ganciclovir prophylaxis days -7 to -2 then standard dose acyclovir. Letermovir pts received standard dose acyclovir & started letermovir IV or PO on day +7 & continued beyond day +100. All pts received uniform intermediate intensity Cy 50 mg/kg / Flu 150 mg/m2/ Thio 5-10 mg/kg / TBI 400 cGy conditioning with CSA/ MMF. Pts were monitored by qPCR twice weekly from approximately day +14-60 & then 1-2 x/weekly days +60-100. 62 [median age 51 years (range 23-66), 46 leukemia, 7 MDS/ MPD, 9 NHL/ HL] historic control pts received double unit grafts with a median unit-recipient HLA-allele match of 5/8 (range 2-7). By day +100, 51 pts developed clinically significant CMV infection for a day +100 cumulative incidence of 82% (95%CI: 70-90). The median viremia onset was 34 days (range 5-74) & 5 pts developed CMV disease by day +100 (3 pulmonary, 2 GI). Initial therapy was with foscarnet in 28 pts & ganciclovir/ valganciclovir in 23. Clinically significant therapy toxicities (renal &/or myelosuppression) were observed in 38/51 (75%) pts (Table 1). By day +100, CMV caused or contributed to 3 pulmonary deaths. 10 pts [median age 48 years (range 24-59), 9 leukemia, 1 MDS/ MPD, median 5/8 (range 3-6) unit-recipient HLA-match] received letermovir prophylaxis (8 IV, 2 PO) (Table 2). All pts engrafted. The day +100 cumulative incidence of clinically significant CMV infection was 0% (p < 0.001 vs controls) (Figure). After letermovir was started, 3 pts had a brief low level CMV viremia that spontaneously resolved without CMV-specific therapy. Prophylaxis was well tolerated & there were no drug toxicities attributed to letermovir. By day +100, one letermovir pt died due to HHV-6 infection. This analysis suggests letermovir prophylaxis is highly effective at mitigating CMV disease, CMV-related mortality, & the need for toxic CMV therapies. Moreover, it has been well tolerated in CBT recipients. While further detailed investigation in a larger population is required, this data is very promising & the extent of the benefit suggests that letermovir could be a cost-effective new standard of care in adult CBT. The duration of needed prophylaxis beyond day +100 in CBT recipients also requires investigation." @default.
• W2912130511 created "2019-02-21" @default.
• W2912130511 creator A5000249065 @default.
• W2912130511 creator A5000852934 @default.
• W2912130511 creator A5002993817 @default.
• W2912130511 creator A5003197311 @default.
• W2912130511 creator A5003831049 @default.
• W2912130511 creator A5031349996 @default.
• W2912130511 creator A5035362303 @default.
• W2912130511 creator A5043510888 @default.
• W2912130511 creator A5044552886 @default.
• W2912130511 creator A5045350627 @default.
• W2912130511 creator A5058746837 @default.
• W2912130511 creator A5064076262 @default.
• W2912130511 creator A5070096873 @default.
• W2912130511 creator A5079087824 @default.
• W2912130511 creator A5082333371 @default.
• W2912130511 date "2019-03-01" @default.
• W2912130511 modified "2023-10-17" @default.
• W2912130511 title "Letermovir Prophylaxis Demonstrates High Efficacy in Adult Cytomegalovirus (CMV) Seropositive Cord Blood Transplant (CBT) Recipients: A Comparison with Pre-Letermovir Era CBT Controls" @default.
• W2912130511 doi "https://doi.org/10.1016/j.bbmt.2018.12.182" @default.
• W2912130511 hasPublicationYear "2019" @default.
• W2912130511 type Work @default.
• W2912130511 sameAs 2912130511 @default.
• W2912130511 citedByCount "5" @default.
• W2912130511 countsByYear W29121305112019 @default.
• W2912130511 countsByYear W29121305112020 @default.
• W2912130511 countsByYear W29121305112023 @default.
• W2912130511 crossrefType "journal-article" @default.
• W2912130511 hasAuthorship W2912130511A5000249065 @default.
• W2912130511 hasAuthorship W2912130511A5000852934 @default.
• W2912130511 hasAuthorship W2912130511A5002993817 @default.
• W2912130511 hasAuthorship W2912130511A5003197311 @default.
• W2912130511 hasAuthorship W2912130511A5003831049 @default.
• W2912130511 hasAuthorship W2912130511A5031349996 @default.
• W2912130511 hasAuthorship W2912130511A5035362303 @default.
• W2912130511 hasAuthorship W2912130511A5043510888 @default.
• W2912130511 hasAuthorship W2912130511A5044552886 @default.
• W2912130511 hasAuthorship W2912130511A5045350627 @default.
• W2912130511 hasAuthorship W2912130511A5058746837 @default.
• W2912130511 hasAuthorship W2912130511A5064076262 @default.
• W2912130511 hasAuthorship W2912130511A5070096873 @default.
• W2912130511 hasAuthorship W2912130511A5079087824 @default.
• W2912130511 hasAuthorship W2912130511A5082333371 @default.
• W2912130511 hasBestOaLocation W29121305111 @default.
• W2912130511 hasConcept C120665830 @default.
• W2912130511 hasConcept C121332964 @default.
• W2912130511 hasConcept C126322002 @default.
• W2912130511 hasConcept C203014093 @default.
• W2912130511 hasConcept C2522874641 @default.
• W2912130511 hasConcept C2776185481 @default.
• W2912130511 hasConcept C2776317777 @default.
• W2912130511 hasConcept C2776724271 @default.
• W2912130511 hasConcept C2777965375 @default.
• W2912130511 hasConcept C2779820661 @default.
• W2912130511 hasConcept C2911091166 @default.
• W2912130511 hasConcept C61511704 @default.
• W2912130511 hasConcept C71924100 @default.
• W2912130511 hasConcept C88879693 @default.
• W2912130511 hasConcept C90924648 @default.
• W2912130511 hasConceptScore W2912130511C120665830 @default.
• W2912130511 hasConceptScore W2912130511C121332964 @default.
• W2912130511 hasConceptScore W2912130511C126322002 @default.
• W2912130511 hasConceptScore W2912130511C203014093 @default.
• W2912130511 hasConceptScore W2912130511C2522874641 @default.
• W2912130511 hasConceptScore W2912130511C2776185481 @default.
• W2912130511 hasConceptScore W2912130511C2776317777 @default.
• W2912130511 hasConceptScore W2912130511C2776724271 @default.
• W2912130511 hasConceptScore W2912130511C2777965375 @default.
• W2912130511 hasConceptScore W2912130511C2779820661 @default.
• W2912130511 hasConceptScore W2912130511C2911091166 @default.
• W2912130511 hasConceptScore W2912130511C61511704 @default.
• W2912130511 hasConceptScore W2912130511C71924100 @default.
• W2912130511 hasConceptScore W2912130511C88879693 @default.
• W2912130511 hasConceptScore W2912130511C90924648 @default.
• W2912130511 hasIssue "3" @default.
• W2912130511 hasLocation W29121305111 @default.
• W2912130511 hasOpenAccess W2912130511 @default.
• W2912130511 hasPrimaryLocation W29121305111 @default.
• W2912130511 hasRelatedWork W1497068331 @default.
• W2912130511 hasRelatedWork W2051280147 @default.
• W2912130511 hasRelatedWork W2051304314 @default.
• W2912130511 hasRelatedWork W2075855379 @default.
• W2912130511 hasRelatedWork W2084164565 @default.
• W2912130511 hasRelatedWork W2108031455 @default.
• W2912130511 hasRelatedWork W2792584385 @default.
• W2912130511 hasRelatedWork W2921203428 @default.
• W2912130511 hasRelatedWork W3135589467 @default.
• W2912130511 hasRelatedWork W3177460120 @default.
• W2912130511 hasVolume "25" @default.
• W2912130511 isParatext "false" @default.
• W2912130511 isRetracted "false" @default.
• W2912130511 magId "2912130511" @default.
• W2912130511 workType "article" @default.